William Blair downgraded Avantor from Outperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/17/2025 | $29.00 → $25.00 | Buy → Neutral | UBS |
| 8/28/2024 | $30.00 | Overweight | Wells Fargo |
| 7/10/2024 | $30.00 → $23.00 | Buy → Neutral | Citigroup |
| 1/4/2024 | $19.50 → $26.00 | In-line → Outperform | Evercore ISI |
| 12/11/2023 | $21.00 → $28.00 | Market Perform → Outperform | TD Cowen |
| 9/28/2023 | $22.00 | Mkt Perform | Bernstein |
| 7/31/2023 | $22.00 → $21.00 | Outperform → In-line | Evercore ISI |
| 7/31/2023 | Outperform → Mkt Perform | William Blair |
4 - Avantor, Inc. (0001722482) (Issuer)
3 - Avantor, Inc. (0001722482) (Issuer)
4 - Avantor, Inc. (0001722482) (Issuer)
RADNOR, Pa., Feb. 19, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that President and CEO, Michael Stubblefield, will present at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, at 11:50 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days
Silq Technologies Corporation, a privately held advanced materials science company, and NuSil Technology LLC, a subsidiary of Avantor Inc., Radnor, Pa. (NYSE:AVTR), and a leading global supplier of high-quality silicones for long-term medical implants, have entered into an agreement to facilitate the utilization of Silq's zwitterionic surface treatment technology on medical devices manufactured with NuSil silicone products. Zwitterion surface technology has been a major subject of research in academia for several decades because of its potential to reduce medical implant-associated infections and complications without the use of antibiotics. Zwitterion functionalized surfaces have also bee
Fourth Quarter 2024 Net sales of $1.69 billion, decrease of 2%; organic growth of 1%Net income of $500.4 million; Adjusted EBITDA of $307.7 millionDiluted GAAP EPS of $0.73; adjusted EPS of $0.27Operating cash flow of $173.3 million; free cash flow of $222.1 millionFull Year 2024 Net sales of $6.78 billion, decrease of 3%; organic decline of 2%Net income of $711.5 million; Adjusted EBITDA of $1,198.8 millionDiluted GAAP EPS of $1.04; adjusted EPS of $0.99Operating cash flow of $840.8 million; free cash flow of $768.3 millionRADNOR, Pa., Feb. 7, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences
Fourth Quarter 2024 Net sales of $1.69 billion, decrease of 2%; organic growth of 1%Net income of $500.4 million; Adjusted EBITDA of $307.7 millionDiluted GAAP EPS of $0.73; adjusted EPS of $0.27Operating cash flow of $173.3 million; free cash flow of $222.1 millionFull Year 2024 Net sales of $6.78 billion, decrease of 3%; organic decline of 2%Net income of $711.5 million; Adjusted EBITDA of $1,198.8 millionDiluted GAAP EPS of $1.04; adjusted EPS of $0.99Operating cash flow of $840.8 million; free cash flow of $768.3 millionRADNOR, Pa., Feb. 7, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences
RADNOR, Pa., Jan. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 7, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscie
Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7%Net income of $57.8 million; Adjusted EBITDA of $302.5 millionDiluted GAAP EPS of $0.08; adjusted EPS of $0.26Operating cash flow of $244.8 million; free cash flow of $204.0 millionRADNOR, Pa., Oct. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fiscal quarter ended September 30, 2024. "Our team delivered another quarter o
UBS downgraded Avantor from Buy to Neutral and set a new price target of $25.00 from $29.00 previously
Wells Fargo initiated coverage of Avantor with a rating of Overweight and set a new price target of $30.00
Citigroup downgraded Avantor from Buy to Neutral and set a new price target of $23.00 from $30.00 previously
SCHEDULE 13G/A - Avantor, Inc. (0001722482) (Subject)
10-K - Avantor, Inc. (0001722482) (Filer)
8-K - Avantor, Inc. (0001722482) (Filer)
RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform
Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees
NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)
SC 13G/A - Avantor, Inc. (0001722482) (Subject)